PsychRights^®
Law Project for Psychiatric Rights

Articles & News

• Doctors told to curb use of Ritalin in hyperactive children Ritalin pills, by Mark Henderson, Science Editor, UK Times, September 24, 2008.
• Senator questions doctors' ties to drug companies, by Emily Ramshaw, The Dallas Morning News, September 24, 2008.
• A Conversation With Nancy C. Andreasen: Using Imaging to Look at Changes in the Brain, by Claudia Dreifus, New York Times, September 16, 2008
• Risks Found for Youths in New Antipsychotics, by Benedict Carey, New York Times, September 15, 2008
• Judge to Unseal Documents on the Eli Lilly Drug Zyprexa, by Mary Williams Walsh, New York Times, September 6, 2008.
• The incidence and prevalence of diabetes in patients with serious mental illness in North West Wales: Two cohorts, 1875–1924 & 1994–2006 compared, by Joanna Le Noury, Afshan Khan, Margaret Harris, Winnie Wong, Dawn Williams, Tony Roberts, Richard Tranter and David Healy, BioMed Central, August 7, 2008.
• Editorial: The Age of Conflicts—of Interest, by Ronald Pies, MD,Psychiatric Times. Vol. 25 No. 9, August 1, 2008.
  • Credibility Gap, Revisited, by Stefan Kruszewski, M.D., Psychiatric News, August 15, 2008, Vol 43, No. 16:23.
• Suicides & Psychiatric Drugs: A report based on data from The National Board of Health and Welfare in Sweden, by Janne Larsson
• To See or Not to See "Schizophrenia" and the Possibility of Full "Recovery," by John Breeding, Ph.D., Journal of Humanistic Psychology, 2008
• Are Our Leading Pediatricians Drug Industry Shills, by Lawrence Diller, MD, SFGate, July 13, 2008
• Psychiatric Group Faces Scrutiny Over Drug Industry Ties, by Benedict Care and Gardiner Harriss, New York Times, July 12, 2008.
• Doctors Say Medication is Overused in Dementia, New York Times, June 24, 2008.
• Key opinion leaders: independent experts or drug representatives in disguise? by Ray Moynihan, visiting editor, British Medical Journal, June 21, 2008.
• US Investigation Into Glaxo And Paxil Widens, Pharmalot, by Ed Silverman, June 20, 2008.
• Glaxo Attracts Questions Over Data in Paxil Studies: Unsealed Report Claims Suicide Risk Was Miscalculated, by By Alicia Mundy and Jeanne Whalen, Wall Street Journal, June 14, 2008; Page A4.
• Medication Effects and the Invisible Wounds of War - Why We Need A Blue Ribbon Panel on Soldier Suicide and Iatrogenic Harm, by Grace E. Jackson, Veterans for Common Sense.
• Irrational Healers, by David Healy, MD, Psychotherapy and Psychosomatics, 77:198-200 (2008)
• Critics say drug firms' payments to doctors are conflict of interest: What they spend: A look at drug company spending in Minnesota — on top specialties and select psychiatrists, by Jeremy Olson and Paul Tosto, Pioneer Press, May 20, 2008.
• Psychiatrists, Children and Drug Industry’s Role, by Gardiner Harris, Benedict Carey and Janet Roberts, New York Times, May 10, 2007.
•  Stealth Marketers: Are doctors shilling for drug companies on public radio? by Shannon Brownlee and Jeanne Lenzer, Slate, May 9, 2008.
• From the American Psychiatric Association Annual Conference, May 9, 2008: Drug Interactions a Common Risk for Schizophrenic Patients.
• To Hell and Back, by Thor Nystom, The University Daily Kansan, May, 2008.
• Studying Placebo Effects Advance the Neuropsychiatric Understanding of Medical Interventions, by Stefan P. Kruszewski, M.D., British Medical Journal, May 7, 2008.
• Eli Lilly's 1st Quarter, 2008, Report on grants.
• Re-focusing upstream: New Drugs, Poorly Recognised Conditions, Genetic Polymorphisms and the Crisis in Mental Health, by Yolande Lucire PhD MB BS DPM FRANZCP (2008).
• "Lethal Drugs Given for Dementia, Times (UK) Online, April 20, 2008.
• Drug Research: To Test or Tout?  Robert Farley, St. Petersburg Times, April 13, 2008.
• One Drug, Two Faces, New York Times, March 25, 2008.
• Lilly Faces Initial Zyprexa Trial: Alaska's Civil Suit Might Set Pattern for Other Actions, by Avery Johnson, Wall Street Journal, February 28, 2008.
• Are Antidepressants Faith-Based Treatment? by  Bruce E. Levine, AlterNe, February 28, 2008.
• Antidepressants: An Untold Story? by Jeanne Lenzer, British Medical Journal, February 27, 2008.
• NJ Legislator: Probe Antipsychotics, Kids & Medicaid, by Ed Silverman, Pharmalot, February 25, 2008.
• Drop in SSRI Prescribing in the United Kingdom Did Not Lead to Youth Suicide Spike, Medscape Medical News, February 21, 2008.
• State (Montana) AG sues two drug companies, by Charles S. Johnson, Helena Independent, State Bureau - 02/22/08
• The Path to Mental Health: Charles Barger Recovered From Illness by Human Connection, by Kathleen Megan, Hartford Courant, February 17, 2008.
• Fox, Big Story w Doug Kennedy on NIU shooter/antidepressants, February 15, 2008.
• Unsealed (except 9 pages) Joseph Glenmullen, MD, analysis of Paxil suicidality kept hidden by GlaxoSmithKline.
• Did GSK trial data mask Paxil suicide risk? Science, February, 2008.
• No Significant Association of 14 Candidate Genes With Schizophrenia in a Large European Ancestry Sample: Implications for Psychiatric Genetics, by Alan R. Sanders, M.D., Jubao Duan, Ph.D., Douglas F. Levinson, M.D., Jianxin Shi, Ph.D., Deli He, B.S., Cuiping Hou, B.S., Gregory J. Burrell, B.S., John P. Rice, Ph.D., Deborah A. Nertney, B.S., Ann Olincy, M.D., Pablo Rozic, M.D., Sophia Vinogradov, M.D., Nancy G. Buccola, A.P.R.N.B.C., Bryan J. Mowry, M.D., Robert Freedman, M.D., Farooq Amin, M.D., Donald W. Black, M.D., Jeremy M. Silverman, Ph.D., William F. Byerley, M.D., Raymond R. Crowe, M.D., C. Robert Cloninger, M.D., Maria Martinez, Ph.D., and Pablo V. Gejman, M.D., American Journal of Psychiatry, AiA:1–10.
• Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy, by Erick H. Turner, M.D., Annette M. Matthews, M.D., Eftihia Linardatos, B.S., Robert A. Tell, L.C.S.W., and Robert Rosenthal, Ph.D, New England Journal of Medicine, 358;3 (January 2008).  This study found that 37 of 38 trials that the F.D.A. viewed as having positive results were published in journals, but only 14 of the 36 studies the FDA viewed as failed or unconvincing made it into journals and 11 of those “conveyed a positive outcome” that was not justified by the underlying F.D.A. review.
• Florida undecided as states sue over costly drug program, Daytona Journal, January 10, 2008.
• The ADHD drug Strattera – actions needed now, Open Letter to the UK's Medicines and Healthcare products Regulatory Agency (MHRA) by Jan Larsson.
• Forced Drugging of Children in Foster Care: Turning Child Abuse Victims into Involuntary Psychiatric Patients, by M. McKay, Ph.D., JOM, Vol. 22, No. 2 (2007).
• Some fear medicines may put foster kids' future health at risk, by Gary Craig, Rochester Democrat and Chronicle, December 10, 200.
• Drugs for ADHD "Not the Answer," BBC, November 12, 2007.
• Danger drugs designed for schizophrenics used to calm children, by Fiona MaCrae, Daily Mail, September 11, 2007.
• Pediatric bipolar disorder: An object of study in the creation of an illness, by David Healy and Joanna Le Noury, International Journal of Risk & Safety in Medicine, 19 (2007) 209–221.
• Senator Grassley seeks thorough review of nursing home use of anti-psychotic drugs, December 6, 2007.
• FDA Science and Mission at Risk Report of the Subcommittee on Science and Technology, prepared for the FDA by the FDA Science Board, November 2007.  This formerly confidential report's three main conclusions are: (1) The FDA cannot fulfill its mission because its scientific base has eroded and its scientific organizational structure is weak, (2) The FDA cannot fulfill its mission because its scientific workforce does not have sufficient capacity and capability, and (3) The FDA cannot fulfill its mission because its information technology (IT) infrastructure is inadequate.
• The Media and the Chemical Imbalance Theory of Depression, by Jonathan Leo & Jeffrey R. Lacasse, Springer Science, (2007)
• Corporate Funding and Conflicts of Interest: A Primer for Psychologists, by Wendy S. Pachter Washington, Ronald E. Fox Human, Philip Zimbardo, and David O. Antonuccio, American Psychologist (December 2007).
• Some fear medicines may put foster kids' future health at risk, by Gary Craig, Rochester Democrat and Chronicle, December 10, 2007.
• Potent Pills: More foster kids getting mood-altering drugs, by Gary Craig, Rochester Democrat and Chronicle, December, 9, 2007.
• Prescription Abuse Seen In U.S. Nursing Homes: Powerful Antipsychotics Used to Subdue Elderly; Huge Medicaid Expense, by Lucette Lagnado, Wall Street Journal, December 4, 2007, A1.
• The Media and the Chemical Imbalance Theory of Depression, by Jonathan Leo & Jeffrey R. Lacasse, Society, 2007.
• Complaint in Arkansas v. Janssen Pharmaceutical Co. for Medicaid Fraud and other claims, filed November 20, 2007.
• Drugs for ADHD "Not the Answer," BBC, November 12, 2007.
• Psychiatry: 60 years in an increasingly corrupt specialty, an interview with psychiatrist Nathaniel Lehrman, November 11, 2007.
• Forced Drugging of Children in Foster Care: Turning Child Abuse Victims into Involuntary Psychiatric Patients, by M. McKay, Ph.D., Journal of Orthomolecular Medicine, Vol. 22, No. 2, 2007
• Danger drugs designed for schizophrenics used to calm children, by Fiona MaCrae, Daily Mail, September 11, 2007.
• World Experts Demand End to Child Drugging in the US - Part II, by Evelyn Pringle, Lawyers & Settlements, October 27, 2007.
• World Experts Demand End to Child Drugging in the US - Part I, by Evelyn Pringle, Lawyers & Settlements, October 27, 2007.
• A Systematic Review of Mortality in Schizophrenia: Is the Differential Mortality Gap Worsening Over Time? by Sukanta Saha, MSc, MCN; David Chant, PhD; John McGrath, MD, PhD, Arch Gen Psychiatry, 2007;64(10):1123-1131.
• From Sweden--Reported suicides – more than 80 percent got psychiatric drugs, well over 50 percent got antidepressants, TransWorld News, October 7, 2007.
• Forced Drugging of Children in Foster Care: Turning Child Abuse Victims into Involuntary Psychiatric Patients, by M. McKay, Ph.D., JOM, Vol. 22, No. 2 (2007).
• Lilly Adds Label Warnings for Mental Drug Zyprexa, by Alex Berenson, New York Times, October 5, 2007
• Arkansas Plans Lawsuit Over Antipsychotics, Pharmalot, September 23rd, 2007, by Ed Silverman
• Worse Than Vioxx: Zyprexa, Risperdal, Clozaril, And Paxil Killed Thousands Of Americans, by Philip Dawdy, Furious Seasons, September 19, 2007.
• The Truth is Not Free, by David Egilman, MD, the doctor from who Jim Gottstein subpoenaed the Zyprexa Papers, about his recent settlement with Eli Lilly (Stipulation and Order, Affidavit), in Sequestered Science, September 11, 2007.
• Psychiatrists' Failure to Inform: Is There Substantial Financial Exposure?, by James B. Gottstein, Esq., Ethical Human Psychology and Psychiatry, Vol 9, No. 2, 117-125 (2007).
• Attorney Subpoenas J&J, AstraZeneca and Lilly for Hidden Antipsychotic Data Part I, Evelyn Pringle, September 10, 2007, Lawyers and Settlements."
• Authorities baffled at baby anti-depressant prescriptions, September 10, 2007, StuffCo.NZ.
• Sidelining Safety — The FDA's Inadequate Response to the IOM, by Sheila Weiss Smith, Ph.D., New England Journal of Medicine, 357:960-963 September 6, 2007, Number 10.
• Biological Psychiatry: A Practice in Search of a Science, by W. Joseph Wyatt & Donna M. Midkiff, Behavior and Social Issues, 15, 132-151 (2006).
• The Future of Drug Safety: Action Steps by Congress, by the Institute of Medicine, September, 2006.
• American Kids Being Drugged To Death, by Evelyn Pringle.
• Psychotropic Drug Makers Bankroll Prescribing Shrinks Part II,  Evelyn Pringle, September 2, 2007, Lawyers and Settlements."
• Psychotropic Drug Makers Bankroll Prescribing Shrinks Part I,  Evelyn Pringle, August 30, 2007, Lawyers and Settlements.", Evelyn Pringle, Lawyers & Settlements, August 22, 2007.
• The Lives they Left Behind: Suitcases Cases from a State Hospital Attic, from  Darby Penney and Peter Stastny.
• Doctor, just a little something for you: Complex sales strategies go way beyond freebies, by By Melissa Healy, Los Angeles Times Staff Writer, August 6, 2007
  • Selling the Patient: Next step: Create the demand; Direct, emotional ads for prescription drugs are everywhere. But they're just one way to get to the consumer, by By Melissa Healy, Los Angeles Times Staff Writer
• The Right Rx for Sadness: Drugs may be an easy choice but not a good one, by By Deborah Kotz, US News & World Report,  7/29/07
• Ped Med: Kid use of mind medicines rising, by Lidia Wasowicz, UPI Senior Science Writer, July 10, 2007.
• Psychiatrists Top List in Drug Maker Gifts, by Gardiner Harris, New York Times, June 27, 2007.
• No MedGuide for Zyprexa after Eleven Years of Death and Injury, by Evelyn Pringle, Op Ed News, June 18, 2007.
• Backlash on bipolar diagnoses in children: MGH psychiatrist's work stirs debate, by Scott Allen Boston Globe, June 17, 2007.
• After Sanctions, Doctors Get Drug Company Pay, by Gardiner Harris and Janet Roberts, New York Times, June 3, 2007
• Drugs Might Breed Violence, Tacoma News Tribune, May 28, 2007.
• Creating Demand for Prescription Drugs: A Content Analysis of Television Direct-to-Consumer Advertising, by Dominick Frosch et. al., Annals of Family Medicine, January/February 2007.
•  Intoxication Anosognosia: The Spellbinding Effect of Psychiatric Drugs, by Peter R. Breggin, MD, Ethical Human Psychology and Psychiatry, Volume 8, Number 3, Fall/Winter 2006.
• New World New Dangers (Zyprexa Papers), by Joshua Slatko, Med Ad News, May 2006.
• Is there a fox in the Medicaid henhouse? Anne Stanton, Northern Exposure.
• Is our pill-popping society losing its mind? Anne Stanton, Northern Exposure
• Psych meds drove my son crazy, Salon, May, 2007.
• Psychotic Reactions And Medicaid: One Man's Quest To Learn The Truth: Meet Ben Hansen, by Ed Silverman, Pharmalot, May 17, 2007.
• Are kids being overdosed?, Northern Express, May 2007.
• Doctors Fail to Recognize Life-Threatening Serotonin Syndrome, by Evelyn Pringle, Op Ed News, May 4, 2007.
• New York Times, Psychiatrists, Children and the Drug Industry's Role, May 10, 2007.
• United States Senate Finance Committee Staff Report on Use of Educational Grants by Pharmaceutical Companies, April, 2007.
• Zyprexa Hole Gets Deeper, by Evelyn Pringle, Lawyers & Settlements, May 1, 2007.
• Following the Script: How Drug Reps Make Friends and Influence Doctors, by Adriane Fugh-Berman and Shahram Ahari, PLoS Medicine, Vol. 4, No. 4, 621-5 (April 2007).
• A National Survey of Physician–Industry Relationships, by Eric G. Campbell, Ph.D., Russell L. Gruen, M.D., Ph.D., James Mountford, M.D., Lawrence G. Miller, M.D., Paul D. Cleary, Ph.D., and David Blumenthal, M.D., M.P.P., New England Journal of Medicine, 356;17, 1742-1750 (2007) 
• Lilly Receives Zyprexa Greetings From Capitol Hill, by Evelyn Pringle, April 27, 2007.
• New York Times, U.S. Wonders if Drug Data Was Accurate, by Alex Berenson, April 25, 2007.
• DSM and the Death of Phenomenology in America: An Example of Unintended Consequences, by Nancy C. Andreasen, Schizophrenia Bulletin vol. 33 no. 1 pp. 108–112, 2007
• Patients Diagnosed Schizophrenic and Bipolar To Boost Seroquel Sales, by Evelyn Pringle, April 11, 2007.
• Senator Grassley asks for Zyprexa Papers and other documents, April 4, 2007.
• Popular Zyprexa linked to illnesses: Schizophrenia drug at center of lawsuit, The Plain Dealer, March 17, 2007.
• Lilly Fraudulently Marketed Zyprexa, Montana Claims, by Margaret Cronin Fisk, Bloomberg News, March 12, 2007.
• Makers of Zyprexa Risperdal and Seroquel Under Fire, by Evelyn Pringle, March 9, 2007.
• Why Clients Should Not Take Psychotherapists into Their Confidence, by Jim Gottstein, ISPS-US Newsletter: Winter, 2006/2007, Volume 7, Issue 3.
• Does compulsory or supervised community treatment reduce 'revolving door' care? Legislation is inconsistent with recent evidence, by Stephen Kisely and Leslie Anne Campbell, British Journal of Psychiatry, 197, 373-374 (2007)
• A Mix of Medicines That Can Be Lethal, by Jane Brody, New York Times, February 27, 2007.
• Taking back the FDA, by Marcia Angell, Boston Globe, February 26, 2007
• Activists Take on Eli Lilly Over Off-Label Sale of Zyprexa, by Evelyn Pringle, Op Ed News, February 26, 2007.
• Off-Label Sales of SSRIs Leads To More Litigation, by Evelyn Pringle, Op Ed News, February 22, 2007.
• Debate Over Children and Psychiatric Drugs, by Benedict Carey, New York Times, February 15, 2007.
• February 14, 2007, New York Times, Judge Rules Drug Documents Must Be Returned to Eli Lilly, by Landon Thomas, Jr.
• February 8, 2007, Secrecy's dangerous side effects: When legal settlements allow companies to hide their mistakes, what we don't know can hurt us, by Richard Zitrin
• February 5, 2007, Nobody Buys Lilly's Innocence Routine About Zyprexa, by Evelyn Pringle
• February 1, 2007, Zyprexa Injury Clock Keeps Ticking Away, by Evelyn Pringle.
• January 25, 2007, Eli Lilly The Habitual Offender, by Evelyn Pringle.
• Comment: The Role of Litigation in Defining Drug Risks, by Aaron S. Kesselheim, MD, JD and Jerry Avorn, MD, Journal of American Medical Association (JAMA), JAMA, January 17, 2007—Vol 297, No. 3; 308-311.
• Neuroleptics – Effects, Risks, Education and Treatment Contexts, by Volkmar Aderhold, presented at Institute for Social Psychiatry at the University of Greifwald, 01/2007
• States Study Marketing of Lilly Pill, by Alex Berenson, New York Times, January 20, 2007.
• Evidence Lacking To Support Many Off-Label Uses Of Atypical Antipsychotics, Medical News Today, January 18, 2007.
• Attorney Asks Eli Lilly to Issue Warning on Zyprexa, by By Evelyn Pringle, Op Ed News, January 14, 2007
• Public Has Right To Know Secrets Revealed In Zyprexa Documents, by Evelyn Pringle, Op Ed News, January 12, 2007
• New York Times, Lilly to Pay Up to $500 Million to Settle Claims, by Alex Berenson, January 4, 2007.
• New York Times, Mother Wonders if Psychosis Drug Helped Kill Son, by Alex Berenson, January 4, 2007.
• PsychRights writes Eli Lilly on December 27, 2006, requesting it send a "Dear Doctor" letter to all health care professions "advising them Zyprexa should not be prescribed to anyone who is not already taking it.
• Video of former Eli Lilly drug rep talking about how they were instructed to downplay Zyprexa's negative effects.
• Court Allows Eli Lilly To Bury Zyprexa Documents, by Evelyn Pringle, Op Ed News, December 21, 2006.
• New York Times, Disparity Emerges in Lilly Data on Schizophrenia Drug, by Alex Berenson, December 21, 2006.
• New York Times, Court Orders Lawyer to Return Documents About an Eli Lilly Drug, December 20, 2006.
• New York Times Editorial, Playing Down the Risks of a Drug: Internal documents offer persuasive evidence that Eli Lilly engaged in questionable behavior to prop up its best-selling drug, December 19, 2006. New York Times, Drug Files Show Maker Promoted Unapproved Use, December 18, 2006.
• New York Times, Eli Lilly Said to Play Down Risk of Top Pill, December 17, 2006. 
• Ann Blake Tracy, Ph.D's December 13, 2006 and and September 13, 2004 FDA testimony on SSRI anti-depressants.
• Forced Drugging and Special Services: A Holocaust in America’s Schools, by Dr. Salvatore Pizzuro, Disability Policy Specialist
• NY TImes, Proof Is Scant on Psychiatric Drug Mix for Young, by Gardiner Harris, November 23, 2006.
• Morbidity and Mortality in People with Serious Mental Illness, by National Association of State Mental Health Program Directors, October 2006.  This study found that the rate of serious morbidity (illness) and mortality (death) of people diagnosed with serious mental illness has accelerated to the point where they are now dying 25 years earlier than the general population.  The Executive Summary does not attribute this to psychiatric drugs, but the body of the report is pretty clear that the major change is the advent of the second generation neuroleptics, also misnomered "atypical antipsychchotics" and the great increase in polypharmacy, the practice of giving multiple psychiatric drugs to patients.
• Biological Psychiatry: A Practice in Search of a Science, by W. Joseph Wyatt & Donna M. Midkiff, Behavior and Social Issues, 15, 132-151 (2006).
• What’s Wrong With a Child? Psychiatrists Often Disagree, New York Times, November 11, 2006.
• The Other Side of Psychopharmacology: A Review of the Literature, by Thomas L. Murray, Jr., Journal of Mental Health Counseling, Volume 28/Number 4/October 2006/Pages 309–337
• Report on Multi-Faceted Grass-Roots Efforts To Bring About Meaningful Change To Alaska's Mental Health Program 
• The Other Youth Drug Problem, Alternative Medicine, December, 2006.
• Soteria – a treatment model and a reform movement in psychiatry, by Volkmar Aderhold - Translated by Peter Stastny - September 2006, In honour of Loren Mosher.
• Uphill Battle-Warning Pharma Customers About Dangers of SSRIs
• Drug Interactions Financial Ties to Industry Cloud Major Depression Study, Wall Street Journal, July 11, 2006.
• Antipsychotic Prescriptions Rise Sharply for Children and Adolescents, National Institute of Mental Health, June 2006.
• Commercial bias in medical journals: Commercial influence and the content of medical journals, by Joel Lexchin, Donald W Light, British Medical Journal, 2006; 332:1444-7.
• Congruencies in Increased Mortality Rates, Years of Potential Life Lost, and Causes of Death Among Public Mental Health Clients in Eight States. by Craig W. Colton, PhD, Ronald W. Manderscheid, PhD, Preventing Chronic Disease, Volume 3: No. 2, April 2006.  This study found deceased public mental health clients had died at much younger ages and lost decades of potential life when compared with their living cohorts nationwide. Clients with major mental illness diagnoses died at younger ages and lost more years of life than people with non-major mental illness diagnoses.
• BBC July 1, 2006, article on Clozapine, Schizophrenia drug 'health risk'.
• In Diabetes, One More Burden for the Mentally Ill, New York Times, June 12, 2006.
• The Plan to Drug America's School Children: The President’s New Freedom Commission On Mental Health, by George Stone, MA, MSW
• Why is it so difficult to stop psychiatric drug treatment? It may be nothing to do with the original problem, by Joanna Moncrieff, Medical Hypothesis, 2006.
• Open Letter to Sally Satel from Michael Allen, Senior Staff Attorney, Bazelon Center for Mental Health Law, May 5, 2006.
• Comparison of Schizophrenia Drugs Often Favors Firm Funding Study, Washington Post, Wednesday, April 12, 2006
• ADHD, Drug Labels, and the FDA: The Continuing Pre-Emption of Public Health, by Grace E. Jackson, MD., March 28, 2006
• FDA Urges Stronger Warnings on ADHD Drugs, Wall Street Journal, March 15, 2006.
• Special Report: Court Filing Makes Public My Previously Suppressed Analysis of Paxil’s Effects, by Peter R. Breggin, MD, Ethical Human Psychology and Psychiatry, Volume 8, Number 1, Spring 2006, 77-84.
  • Full Report (sworn written testimony filed in the Lacuzong Case).
• Lifetime suicide rates in treated schizophrenia: 1875-1924 and 1994-1998 cohorts compared, by D. Healy, M. Harris, R. Tranter, P. Gutting, R. Austin, G. Jones-Edwards and A.P. Roberts, British Journal of Psychiatry (2006), 188, 223-228.  This study documents how the suicide rate went from one half of one percent before the advent of neuroleptics (and deinstitutionalization) to four percent in the modern era where neuroleptics are the standard treatment.
• The Gaithersburg Address: ADHD Medications: Risks and Benefits, Sue Parry's Testimony to the FDA, February 9, 2006.
•  The latest mania: Selling bipolar disorder, by D. Healy, PLoS Med 3(4): e185 (2006).
• The Under Reported Story: ADHD, Stimulants, and the FDA, by Grace E. Jackson, MD, February 18, 2006.
• Associated Press, February 10, 2006: FDA Panel recommends "Black Box" warning regarding lethal potential of ADHC Drugs (Ritalin, etc.).
• Trends in Prescribing of Antipsychotic Medications for US Children, by William O. Cooper, MD, MPH; Patrick G. Arbogast, PhD; Hua Ding, MS; Gerald B. Hickson, MD; D. Catherine Fuchs, MD; Wayne A. Ray, PhD, Ambulatory Pediatrics, 2006;6:79–83, documents the astonishing increase in prescriptions of neuroleptics to children.
• FDA Urges Stronger Warnings on ADHD Drugs, Wall Street Journal, March 15, 2006.
• Stimulant Treatment of ADD/ADHD: Concerns about Adverse Effects, DuBose Ravenel, M.D., F.A.A.P., written testimony to FDA for March 22, 2006 Pediatric Committee Meeting.
• The Australian: Dark side of a wonder drug, March 28, 2006.
• The Age (Australia): Children on ADHD drugs suffer strokes, March 27, 2006.
• ADHD: The new stimulant threat, An estimated six million of our children are taking powerful prescription amphetamines known to speed freaks as the champagne of uppers.
• Attention Surplus? Re-examining a Disorder, by Paul Steinberg, MD, New York Times, March 7, 2006.
• Disposition of Emergency Department Visits for Drug-Related Suicide Attempts by Adolescents: 2004, February, 2006, by the Drug Abuse Warning Network (DAWN),  in Office of Applied Studies (OAS), Substance Abuse and Mental Health Services Administration (SAMHSA).  This review of emergency room visits found that over 40% of the over 15,000 adolescent suicide attempts resulting in emergency room visits in 2004 involved psychiatric drugs.
• Medication-Free Research in Early Episode Schizophrenia: Evidence of Long-Term Harm? by John R. Bola, Schizophrenia Bulletin vol. 32 no. 2 pp. 288–296, 2006, doi:10.1093/schbul/sbj019.
• The Under Reported Story: ADHD, Stimulants, and the FDA, by Grace E. Jackson, MD, February 18, 2006.
• Associated Press, February 10, 2006: FDA Panel recommends "Black Box" warning regarding lethal potential of ADHC Drugs (Ritalin, etc.).
• Pediatric bipolar disorder: An object of study in the creation of an illness, by David Healy and Joanna Le Noury, International Journal of Risk & Safety in Medicine, 19 (2007) 209–221.
• Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits, by Jennifer Glass, Krista L Lanctôt, Nathan Herrmann, Beth A Sproule, Usoa E Busto, British Medical Journal, BMJ, doi:10.1136/bmj.38623.768588.47 (published 11 November 2005).
• Childhood trauma, psychosis and schizophrenia: a literature review with theoretical and clinical implications, ACTA Psychiatrica Scandinavica,  2005: 112: 330–350
• Zyprexa IM Caution Issued in Some Countries But Not U.S, by Mark Moran, Psychiatric News, April 15, 2005, Vol. 40 No. 8.
• Consumer Advertising of Psychiatric Medications Bias Public Against Non-pharmocological Treatment,  by Jeffrey R. Lacasse, Ethical Human Psychology and Psychiatry, Vol. 7, No. 3, Fall/Winter 2005.
• Mental Illness and the Freedom to Refuse Treatment: Privilege or Right, by Ron Bassman, Professional Psychology: Research and Practice, 2005, Vol 36, No. 5, 488-497.
• Confidential Master Settlement Agreement in Zyprexa I,  filed with the Securities and Exchange Commission, November 3, 2005.
• Trouble in Prozac Nation, Fortune Magazine, November 2005.
• Bitter Pills: They're prescribed to millions, but do the new antidepressants work? And are they worth the risk? Time Magazine, Asia Edition, November 14, 2005.
  • Taking on Drug Defenders.
• How the Legal System Can Help Create a Recovery Culture in Mental Health Systems,
• New Drugs, New Problems, by Dr. Yolande Lucire, Australian Journal of Forensic Sciences, 37:1, in Press as of November 6, 2005.
• Rethinking schizophrenia: its original nature, its drug-altered character, and thoughts about its treatment, by Nathaniel S. Lehrman, M.D., presented at the International Center for the Study of Psychiatry and Psychology (ICSPP) October, 2005, Conference.
• Drug Secrets: What the FDA isn't telling, Slate, September 27, 2005, by Jeanne Lenzer.
• GPs to stop prescribing antidepressants blamed for suicidal feelings in under-18s, The Guardian (UK), September 28, 2005.
• Little Difference Found in Schizophrenia Drugs, The New York Times, and Generic Fares Well In Big Psychiatry Study: Newer, Costlier Drugs Have Little Advantage for Schizophrenia;Comparative Data on Side Effects in the Wall Street Journal September 20, 2005, discuss the just released study from the New England Journal of Medicine, Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia, demonstrating little if any more benefit or fewer problems with the so-called "atypical" neuroleptics, such as Zyprexa, Risperdal, Geodon, and Seroquel that cost so much more over the older ones, such as Thorazine, Haldol, Prolixin and Navane.
• First trimester antidepressant risk, from Australian Dr., describes SSRIs doubling the risk of birth defects if used during pregnancy.
• New Antipsychotic Drugs Worrying, new study shows, Globe and Mail, September 13, 2005.
• Are ADHD drugs safe? Report finds little proof, Tacoma Tribune, September 13th, 2005, reports the most comprehensive scientific analysis of the drugs to date has found little evidence that they are safe, that one drug is more effective than another or that they help school performance.
• Anatomy of an Epidemic: Psychiatric Drugs and the Astonishing Rise of Mental Illness in America, by Robert Whitaker, Ethical Human Psychology and Psychiatry, Volume 7, Number I: 23-35 Spring 2005.
• My Whole Body is Sick . . . My Life is Not Good:  A Rwandan asylum seeker attends a psychiatric clinic in London, by Derek Summerfield, Ch. 6 from: Forced Migration and Mental Health. Rethinking the Care of Refugees and Displaced Persons (ed D. Ingleby) New York: Springer 2005.
• Top-selling drug (Seroxat/Paxil) linked to increased suicide risk, London Times, August 22, 2005.
• Bay Area Street Smart's August, 2005 series on psychiatric abuses.
  • Homelessness and Psychiatric Abuse
  • Toxic Psychiatric Drugs: Interview with Robert Whitaker
  • Electroshock Must Be Banned
  • Zyprexa: A Prescription for Disease & Death
  • The Dangers of Antidepressants
  • Mental Health Policy: Humane or Reactionary?
• Officials Bicker as Mentally Ill Wither, Los Angeles Times, August 3, 2005.
• Context and Cooperation in Strategic Therapy: Toward a Contextual Mental Health (Draft Copy July 28, 2005) by
  George Stone, MA, MSW.
• Huge Mental Health Victory for MN Families: MN parents & children protected from mental health coercion & universal screening, Edwatch, July 18, 2005
• How to Quit the Cure, Newsweek, August 8, 2005.
• Death of the Magic Bullet, Sunday (London) Times, July 31, 2005.
• Bitter Pill, in Columbia Journalism Review, August 2005, describes the Media's contributing role to false and misleading information about the safety and benefits of new drugs.
• A Curious Consensus: “Brain Scans Prove Disease?” By Grace E. Jackson, MD, July 10, 2005 (Revised Sept. 2005)
• Stefan P Kruszewski: Schizophrenia and Epilepsy: Untenable Link from Flawed Research Design  (5 July 2005)  responding to Ping Qin, Huilan Xu, Thomas Munk Laursen, Mogens Vestergaard, and Preben Bo Mortensen, Risk for schizophrenia and schizophrenia-like psychosis among patients with epilepsy: population based cohort study BMJ 2005; 331: 23.
• Three Part Washington Post Series by Shankar Vedantam on Mind and Culture: Psychiatry's Missing Diagnosis
  • Patients' Diversity Is Often Discounted, June 26, 2005.
  • Social Network's Healing Power Is Borne Out in Poorer Nations, June 27, 2005.
  • Racial Disparities Found in Pinpointing Mental Illness, Tuesday, June 28, 2005.
• June 1, 2005, Freedom of Information Act transmittal of Adverse Reactions to Olanzapine (Zyprexa).  (13 MB)
• The Marketization of Depression: Prescribing SSRI Antidepressants to Women, by Janet Currie, Women and Health Protection, May 2005.
• House of Commons Health Committee: The Influence of the Pharmaceutical Industry, March 22, 2005.
• What Can We Learn from Medical Whistleblowers? Their experiences paint a troubling picture of American medicine's ties with the pharmaceutical industry, by Jeanne Lenzer in the Public Library of Science (PLOS), May 27, 2005, Volume 2, Issue 7.
  • Why PLoS Sponsored a Roundtable of Medical Whistleblowers
• The Ethics of Electroconvulsive Therapy (ECT) by Loren R. Mosher MD and David Cohen, PhD, Journal of the American Medical Association October 2003, Volume 5, Number 10
• The Influence of Big Pharma: Wide Ranging Report Identifies Many Areas of Influence and Distortion, British Medical Journal, April 16, 2005,  BMJ 2005;330:857–8
• Opportunity cost of antidepressant prescribing in England: analysis of routine data, by Sandra Hollinghurst, David Kessler, Tim J Peters, David Gunnell, British Medical Journal (BMJ), BMJ, doi:10.1136/bmj.38377.715799.F7 (published 18 March 2005)
• In its February 19, 2005, issue, the British Medical Journal (BMJ) published three articles about SSRI Antidepressants and suicide.
  • Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials
  • Suicide, Depression and Antidepressants: Patients and Clinicians Need to Balance Benefits and Harms
  • Pills, Thrills and Bellyaches (Editorial)
• Randomized Controlled Trials: Evidence Biased Psychiatry, By David Healy, MD MRCPsych
• An Examination of Eli Lilly and Company's Contentions that the BMJ Prozac Documents were Never Missing and Have No Significance, by Dr. Peter Breggin, January 12, 2005.
• Dr. Grace Jackson's June 6, 2004 Public Lecture, "What Doctors May Not Tell You About Psychiatric Drugs," to the UCE Centre for Community Mental Health, in Birmingham, England.
• California Court bans electroshock at Santa Barbara College Hospital on January 5, 2005 in Akkerman v. Johnson.
• PsychRights 2004 Year-End Report.
• FDA Scientists Issued Early Warnings on Drug Approvals: Staff Survey Echoes Safety Concerns Raised by Dr. Graham in Senate
• In Re: Robert S, November 18, 2004, Illinois Supreme Court Opinion holding the State of Illinois violated Robert's constitutional rights, as a pretrial detainee in a forced medication proceeding based on his purported best interests, by not notifying his criminal defense attorney and failing to appoint a psychiatrist as an independent expert witness, rather than a psychologist.
• PsychRights Joins MindFreedom Shield Program
  • Advance Directives at PsychRights
• National Mental Health Screening of children effort likely  to be orchestrated by drug companies to increase percentage of kids on psychiatric drugs.
  • Form letter invoking right to prevent screening under the Protection of Pupil Rights Amendment (PPRA).
  • Send a Message to Congress Opposing Funding for Screening
  • Bush Wants to Screen All Children for Mental Illness, by Keith Hoeller, Ph.D., September 19, 2004, editor of Review of Existential Psychology & Psychiatry.
  • On November 12, 2004, Jim Gottstein of the Law Offices of James B. Gottstein wrote a letter to  Ted Stevens, chair of the Senate Appropriations Committee regarding funding for screening.
• Mental Health "Parity": Why Waste Money, Endanger Civil Liberties? Special to The Seattle Times, Thursday, February 10, 2005, By Keith Hoeller
• Ontario Electroshock ("ECT") Statistics 2000-2002 (third draft), compiled by Don Weitz.
• International Consensus: ADHD and Abuse in the Prescription of Psychopharmaceutical Drugs to Minors (January 2005) "Giu' Le Mani Dai Bambini®" National Campaign for the Defence of Children's Right to Health.
• Drug firms lagging on openness: Despite vow, few studies publicized, Boston Globe,  January 9, 2005.
• The Prozac Paradox: Why antidepressants may exacerbate depression and anxiety in some kids and teens, Popular Science, January 2005.
• The Dictionary of Disorder, by Alix Spiegel: How one man revolutionized psychiatry, The New Yorker, January 3, 2005, posted December 27, 2004.
• FDA to Review "Missing" Drug Company Documents, British Medical Journal, December 31, 2004, BMJ VOLUME 330 1 JANUARY 2005 bmj.com.
  • Copy of the 1988 Document publicly released January 4, 2005.  (7 MB)
  • Dispute Puts a Medical Journal Under Fire, New York TImes, January 17, 2005.
• FDA Scientists Issued Early Warnings on Drug Approvals: Staff Survey Echoes Safety Concerns Raised by Dr. Graham in Senate Testimony, Union of Concerned Scientists, December, 2004.
• Dr. Joseph Glenmullen's Q&A from ABC News on Anti-Depressants.
• At F.D.A., Strong Drug Ties and Less Monitoring, New York Times, December 6, 2004.
• Scientific American Mind, December 2004 Issue, Treating Depression: Pills or Talk?
• Crisis deepens at the US Food and Drug Administration, British Medical Journal, December 4, 2004, BMJ 2004;329:1308 (4 December), doi:10.1136/bmj.329.7478.1308
• Contracts Keep Drug Research Out of Reach, New York Times, November 29, 2004.
• Public interest group accuses FDA of trying to discredit whistleblower, British Medical Journal, November 27, 2004
• Forbes: Antidepressants Tied to Abnormal Bleeding
• Minutes of Evidence, United Kingdom Parliament, House of Commons, Select Committee on Health, October 14, 2004.
  • David Healy, MD Memorandum
  • David Healy, MD, Statement of Competing Interests
  • Manufacturing Consensus, by David Healy MD FRCPsych. In Press in Greenslit, N (Ed). Pharmaceutical Cultures: Marketing Drugs and Changing Lives in the US Rutgers University Press as found on the United Kingdom Parliament website.
• New York Times Magazing, November 21, 2004, The Antidepressant Dilemma.
• Stun gun deaths raise drug-link questions, Sacramento Bee, November 13, 2004
• Bush's plan to screen for mental health meets opposition in Illinois, British Medical Journal, November 6, 2004.
• Biomedical Bias of the American Psychiatric Association, by Duncan B. Double, MA, MRCPsych.  This is an academic article that deconstructs the American Psychiatric Association's September, 2003 "Statement" responding to the Fast for Freedom in Mental Health.
• Psychiatric Fraud and Force: A Critique of E. Fuller Torrey, by Thomas Szasz, M.D., 416 Journal of Humanistic Psychology, Vol. 44 No. 4, Fall 2004 416-430.
• 2004 letter responding to assertions that (1) ADHD is generally considered to be a neurochemical disorder, (2) ADHD is present from birth, and (3)
  ADHD is not caused by poor parenting, dysfunctional families, poor schooling or nutrition.
• Did major media outlets fail to ask the right questions about depression study? British Medical Journal, September 25, 2004.
• Seroxat (Paxil) and Prozac 'can make people homicidal,' The Guardian, September 21, 2004.
• Bush Wants to Screen All Children for Mental Illness, by Keith Hoeller, Ph.D., September 19, 2004, editor of Review of Existential Psychology & Psychiatry.
• Presentation before the FDA on September 13, 2004, Lawrence Diller, M.D.
• FDA Urged Withholding Data on Antidepressants Makers Were Dissuaded From Labeling Drugs as Ineffective in Children, Washington Post, Friday, September 10, 2004.
• A Commentary on the Proposal to Observe the Effects Of a Single Dose of Amphetamine in Children, by Jonathan Leo, Ph.D., Submitted for the Food and Drug Administration’s Meeting of the Pediatrics Ethics Subcommittee of the Pediatric Advisory Committee on September 10, 2004.
• Journals Insist Drug Manufacturers Register All Trials, in the Washington Post, September 8, 2004
• GlaxoSmithKline Settles NY Fraud Suit, promising to disclose all drug trial results, August 26, 2004.  See, Consent Decree (Settlement) and Press Release.
• Prozac Nation: Is the Party Over? By Richard C. Morais,  Forbes, August 20, 2004.
• Bush plans to screen whole US population for mental illness, Jeanne Lenzer New York British Medical Journal, Vol. 328, 19 June 2004, page 1458, bmj.com (PDF Version).
• Secret US report surfaces on antidepressants in children, by Jeanne Lenzer New York, British Medical Journal, Vol.329 7 AUGUST 2004, page 307 bmj.com.
• Janssen, July 21, 2004 "Dear Health Care Provider" Letter for Risperidone (Risperdal).
  • April 19, 2004, FDA Warning Letter to Janssen about its previous Dear Health Care Provider being "false or misleading," which resulted in the July 21, 2004  letter.
• Clinical Trials Controversy Spotlights Flawed System, by Jim Rosack,  Psychiatric News July 16, 2004, Volume 39 Number 14.
• July 2, 2004, Pennsylvania whistleblower lawsuit by Harvard trained psychiatrist Stefan P. Kruszewski, in Pennsylvania over Drug company/Pennsylvania State corruption involving drugging abuses, including deaths of children.
• Psychiatric Polypharmacy: A Word of Caution, June 2004, Protection and Advocacy, Inc.
• FDA Revisits Issue Of Antidepressants for Youths: New Analysis May Pressure Agency to Set Limit on Use Because of Suicide Risk, by Anna Wilde Mathews, Wall Street Journal, August 5, 2004; Page A1.
• The Biology of Mental Illness, by Jonathon Leo in Society, July/August 2004.  Dr. Leo goes through the lack of any evidence supporting the current conventional wisdom that mental illness is an actual disease. 
• FDA’s counsel accused of being too close to drug industry, Jeanne Lenzer New York, BMJ VOLUME 329 24 JULY 2004.
• Mum free after murder bid.
• Eli Lilly, Zyprexa and the Bush Family, by Bruce Levine in Z Magazine Online, May 2004 Volume 17 Number 5
• The evidence base: rock of certainty or shifting sands? by John Dewhurst, retired pharmaceutical physician, British Medical Journal, April 17, 2004, BMJ 2004;328:963 (17 April), doi:10.1136/bmj.328.7445.963
• All the Things They Taught Us That Were Wrong, by Thomas A. M. Kramer, MD Psychopharmacology Today,  2004;6(2):e19.
• Interview of Dr. Loren Mosher in the April 2004 issue of Mental Health Today (UK).
• LA Times, April 6, 2004: FDA Sat on Report Linking Suicide, Drugs
• New York Times' February 25, 2004 article on Eli Lilly and Zyprexa, which includes that "In the last year, doctors have learned that its side effects include diabetes, stroke and death."
• Allen Jones' Full Whistle-Blower Report on Drug Company influence on states' drug purchases.
  • NY Times 2/1/2004,  article, Making Drugs, Shaping the Rules about this.
• Drug report barred by FDA/Scientist links antidepressants to suicide in kids, Sunday, February 1, 2004 (SF Chronicle), Rob Waters, Special to The Chronicle
• Talking back to Prozac: David Healy was among the first psychiatrists to prescribe Prozac. Now he's one of the fiercest critics of Big Pharma's "marketing" of depression. Did his outspoken views cost him his job? By Joshua Kendall, The Boston Globe, 2/1/2004
• Antidepressants & Suicide: Lawsuits target drug makers, New Jersey Star-Ledger, Friday, January 30, 2004.
• Antidepressant Makers Withhold Data on Children, washingtonpost.com, By Shankar Vedantam, Washington Post Staff Writer, Thursday, January 29, 2004; Page A01
• Oh, behave! By Joe Studwell Financial Times, Published: January 23 2004
• Allen Jones May 8, 2004, lawsuit against the Pennsylvania Inspector General's office over retaliation for filing a previous civil rights action and for speaking out about corruption in Pennsylvania's psychiatric drug purchases.
• A Suicide Side Effect? What parents aren't being told about their kids' antidepressants.  San Francisco Chronicle, January 4, 2004.
• The psychiatric protection order for the “battered mental patient,” by Thomas Szasz. BMJ (British Medical Journal) Vol.  327 20–27 December 2003, 1449-51.
• Over-medication: a growing crisis: Aggressive marketing a major culprit, By Lou Dobbs.  October 2, 2003.
• Does Medicaid Pay Too Much for Prescription Drugs? A Case Study of Atypical Anti-Psychotics, by Mark Duggan, University of Chicago and NBER
• Is it Prozac or Placebo.
• Psychiatric Medications, Illicit Drugs, & Alcohol, By Bruce Levine
• Frontline Investigates whether FDA Assuring Drug Safety.
• Civil Commitment Due To Mental Illness And Dangerousness: The Union Of  Law And Psychiatry Within A Treatment-Control System, by Bernadette Dallaire, Michael McCubbin, Paul Morin, and David Cohen,   Sociology of Health & Illness; Sep2000, Vol. 22 Issue 5, p679, 21p 
• SSRI discontinuation syndrome in Postgraduate Medicine
• Treatment-induced Suicide: Suicidality as a potential effect of psychiatric drugs, by Peter Lehman in, Journal of Critical Psychology, Counselling and Therepy, Vol 2, No. 1, (Spring 2002).
• "What if ADHD Really Doesn't Exist?" by: Tony Zizza, AbleChild.org
• Critique of Medical-Coercive Psychiatry by Ron Leifer M.D.
• Coercive psychiatry, human rights and public participation by Richard Gosden
• The Effects of Medicating or Not Medicating on the Treatment Process by Bertram P. Karon, Ph.D.
• Three Part Series: Problems With Forced Psych Drug Treatment, by Nicholas Regush
  • Part One
  • Part Two
  • Part Three
• Trauma Within the Psychiatric Setting:  A Preliminary Empirical Report, by Karen J. Cusack, B. Christopher Frueh, Thom Hiers, Samantha Suffoletta-Maierle, and Sandy Bennett, Administration and Policy in Mental Health, Vol. 30, No. 5, May 2003 (2003)
•  Unwarranted Court Ordered Medication: A Call to Action
• The Other Drug War: Big Pharma’s 625 Washington Lobbyists from Public Citizen, July 2001.
• The Right to Refuse Treatment by Grace E. Jackson, MD
• Therapeutic Jurisprudence: Embracing a Tainted Ideal, by Arthur G. Christean
• ADHD: Total, 100% Fraud, by Fred A. Baughman Jr., Neurologist, Pediatric Neurologist, Fellow, American Academy of Neurology
• Insanity Pleas in the City Limits Monthly, May 2000.
• The MacArthur Coercion Study Executive Summary February 2001
• Mandated Community Treatment: Beyond Outpatient Commitment, by John Monahan, Ph.D, Richard J. Bonnie, LL.B, Paul S. Appelbaum, M.D., Pamela S. Hyde, J.D., Henry J. Steadman, Ph.D., and Marvin S. Swartz, M.D.
• The Rights of Users of the Mental Health System: The Tight Knot of Power, Law, and Ethics, by Michael McCubbin & David Cohen - June 1999.
• Do Psychiatric Inmates in New York Have the Right to Refuse Drugs?  An Examination of Rivers Hearings in the Brooklyn Court
• Why Psychiatric Drugs Are Always Bad by Douglas C. Smith, M.D
• The Bureaucratic Destruction of Patients' Faith in Their Doctors:  Public Psychiatry's Negative Lessons for General Medicine, by Nathaniel S. Lehrman, Bulletin of the New York Academy of Medicine, Winter 1994, Vol. 71, No. 2; 194-217.
• On Being Sane In Insane Places, by David L. Rosenham, Science, Vol. 179 (Jan. 1973), 250-258.  This is the classic study where eight of Rosenhan's friends and grad students posed as mentally ill and the psychiatrists couldn't tell (but the other patients could).
• Twenty-Nine Medical Causes of “Schizophrenia,” Excerpted from Nutrition and Mental Illness, by the late Carl C. Pfeiffer, Ph.D., M.D.

FAIR USE NOTICE: These links may contain copyrighted (© ) material the use of which has not always been specifically authorized by the copyright owner. Such material is made available to advance understanding of ecological, political, human rights, economic, democracy, scientific, moral, ethical, and social justice issues, etc. It is believed that this constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, this material is used for non-profit educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml. If you wish to use copyrighted material for purposes of your own that go beyond 'fair use', you must obtain permission from the copyright owner.  Any copyright owner who objects to the use of their copyrighted material should send an e-mail to webmaster@psychrights.org.

Last modified 9/24/2008
Copyright © 2003-2008 Law Project for Psychiatric Rights. All Rights Reserved